Approval Year
Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 06:41:13 GMT 2023
by
admin
on
Sat Dec 16 06:41:13 GMT 2023
|
Protein Sub Type | |
Sequence Type | COMPLETE |
Record UNII |
66DDF797LP
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
UCSF-FDA TRANSPORTAL |
SLCO1B3
Created by
admin on Sat Dec 16 06:41:15 GMT 2023 , Edited by admin on Sat Dec 16 06:41:15 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
66DDF797LP
Created by
admin on Sat Dec 16 06:41:15 GMT 2023 , Edited by admin on Sat Dec 16 06:41:15 GMT 2023
|
PRIMARY | |||
|
Solute_carrier_organic_anion_transporter_family_member_1B3
Created by
admin on Sat Dec 16 06:41:15 GMT 2023 , Edited by admin on Sat Dec 16 06:41:15 GMT 2023
|
PRIMARY |
From | To |
---|---|
1_459 | 1_485 |
1_463 | 1_474 |
1_465 | 1_489 |
Glycosylation Type | HUMAN |
Glycosylation Link Type | Site |
---|---|
N | 1_134 |
N | 1_145 |
N | 1_151 |
N | 1_445 |
N | 1_503 |
N | 1_516 |
Related Record | Type | Details | ||
---|---|---|---|---|
|
INHIBITOR -> TRANSPORTER |
IC50
|
||
|
INHIBITOR -> TRANSPORTER |
IC50
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
NON-SUBSTRATE -> TRANSPORTER |
|
||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
|
||
|
SUBSTRATE -> TRANSPORTER |
|
||
|
SUBSTRATE -> TRANSPORTER |
Coordination with OATP1B3 inhibitors (e.g. rifampicin, cyclosporine, etc.) could lead to an increase in systemic exposure of the active metabolite.
|
||
|
SUBSTRATE -> TRANSPORTER | |||
|
TISSUE EXPRESSION->TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
The results suggest that KLISYRI has no clinically meaningful effect on the PK of drugs mediated by OATP1B3
IC50
|
||
|
SUBSTRATE -> TRANSPORTER |
|
||
|
NON-SUBSTRATE -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
IC50
|
||
|
INHIBITOR -> TRANSPORTER |
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
IC50
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER |
|
||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
IC50
|
||
|
SUBSTRATE -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER |
IC50
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
substrate used: Amantinin, Bosentan, Bromsulphthalein (BSP), Rosuvastatin
|
||
|
INHIBITOR -> TRANSPORTER |
|
||
|
SUBSTRATE -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
IC50
|
||
|
INHIBITOR -> TRANSPORTER |
IN VITRO
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER |
|
||
|
SUBSTRATE -> TRANSPORTER |
|
||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
IC50
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
|
||
|
SUBSTRATE -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER |
|
||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
IC50
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
IC50
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER |
|
||
|
INHIBITOR -> TRANSPORTER |
|
||
|
INHIBITOR -> TRANSPORTER |
In vitro, selinexor inhibits OATP1B3 with an IC50 value of 6.20 μM.
IC50
|
||
|
INHIBITOR -> TRANSPORTER |
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER |
|
||
|
INHIBITOR -> TRANSPORTER |
Ki
|
||
|
INHIBITOR -> TRANSPORTER |
substrate used: Cholyl-glycylamido-fluorescein (CGamF)
|
||
|
SUBSTRATE -> TRANSPORTER |
|
||
|
INHIBITOR -> TRANSPORTER |
IN VITRO
|
||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
|
||
|
INHIBITOR -> TRANSPORTER |
|
||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Molecular Formula | CHEMICAL |
|
||||
MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|